Metamizol Noridem (Metamizole Sodium Monohydrate)

Metamizole acts by inhibiting cyclooxygenase enzymes, which reduces the synthesis of prostaglandins that mediate pain and fever. In addition, it influences central pain pathways in the spinal cord and brain, providing analgesic and antipyretic effects without engaging opioid receptors.

The specific dose of Metamizol Noridem is determined by the prescribing clinician based on the patient’s condition, age, weight, and clinical response. Healthcare professionals calculate the appropriate amount and route—intravenous or intramuscular—according to established medical guidelines.

Safety data for Metamizol Noridem in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To request Metamizol Noridem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Metamizol provides potent analgesia and antipyresis without the gastrointestinal ulcer risk commonly associated with traditional NSAIDs and without the respiratory depression linked to opioids. However, it carries a rare but serious risk of agranulocytosis, which is not typical for most NSAIDs, so patient monitoring differs.

Metamizol Noridem should be stored at ambient temperature, preferably below 25 °C. Keep the vials in their original packaging, protect them from direct light, and avoid exposure to moisture to maintain product stability.

Metamizol Noridem is supplied as a sterile injection solution for intramuscular or intravenous administration. The healthcare professional selects the appropriate route, prepares the dose under aseptic conditions, and injects the medication according to standard clinical protocols.

The most serious risks include agranulocytosis, a potentially fatal drop in white‑blood‑cell count, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, skin changes, or sudden hypotension, and treatment should be stopped immediately if these occur.

Metamizol Noridem is contraindicated in individuals with a known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis, and those with severe liver or kidney impairment where the risk outweighs benefit. It should also be avoided in pregnant or breastfeeding women unless clearly indicated by a physician.